Analysts Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Target Price at $133.00

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have earned a consensus recommendation of “Moderate Buy” from the eleven research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $133.00.

Several analysts have issued reports on ORKA shares. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Guggenheim reissued a “buy” rating and set a $200.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. BTIG Research restated a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Finally, Wedbush restated an “outperform” rating and issued a $165.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 11th.

Insider Activity

In other news, CEO Lawrence Klein sold 2,452 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $95.71, for a total transaction of $234,680.92. Following the completion of the transaction, the chief executive officer owned 923,128 shares of the company’s stock, valued at approximately $88,352,580.88. The trade was a 0.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Arjun Agarwal sold 560 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $95.71, for a total transaction of $53,597.60. Following the completion of the transaction, the senior vice president owned 14,752 shares in the company, valued at approximately $1,411,913.92. This trade represents a 3.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 124,004 shares of company stock worth $11,606,239. 23.49% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Oruka Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Sei Investments Co. lifted its holdings in shares of Oruka Therapeutics by 136.0% during the 1st quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock worth $1,120,000 after acquiring an additional 13,164 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in Oruka Therapeutics in the first quarter worth $5,543,000. Handelsbanken Fonder AB bought a new position in Oruka Therapeutics in the second quarter valued at $15,313,000. The Manufacturers Life Insurance Company increased its stake in Oruka Therapeutics by 18.3% in the first quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock valued at $3,559,000 after acquiring an additional 11,205 shares during the last quarter. Finally, BlackRock Inc. purchased a new stake in Oruka Therapeutics during the second quarter valued at about $474,916,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Price Performance

Shares of ORKA stock opened at $92.20 on Friday. The company’s fifty day simple moving average is $95.87 and its two-hundred day simple moving average is $72.78. Oruka Therapeutics has a 1 year low of $14.66 and a 1 year high of $115.51. The stock has a market capitalization of $6.10 billion, a price-to-earnings ratio of -45.42 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Equities research analysts anticipate that Oruka Therapeutics will post -2.42 EPS for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.